Compare Elastic NV (ESTC) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Elastic NV vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Elastic NV trades at $90.56 (market cap $9.90B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Elastic NV is far larger — about 10.2× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Elastic NV is trading nearer its 52-week high, Maravai LifeSciences Holdings Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Elastic NV for 11 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| ESTC | MRVI | |
|---|---|---|
Market Cap | $9.90B | $972.90M |
Volume | 1,629,456 | 4,325,710 |
Sector | Technology | Health |
52-Week High | $99.91 | $9.00 |
52-Week Low | $43.30 | $2.83 |
Typical Hold Time | 11 Days | 0 Days |
Enterprise Value | $9.04B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Elastic (ESTC) trades at $94.32, down 1.26% on the day, with a bullish technical signal from moving averages and strong analyst support. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Recent product launches, including a metrics platform and serverless vector database, highlight innovation in AI and data search. Revenue grew to $1.48 billion in 2025, with a projected increase to $1.8 billion in 2026, though 2025 net income was negative.
The outlook is positive, driven by product innovation and earnings beats, but high valuation ratios and negative net income in 2025 pose risks. Analyst consensus is bullish with a $83.18 price target, suggesting potential upside. Key risks include execution challenges and competitive pressures in the software sector.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Elastic NV
Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.
Read more on ESTC →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
